AFMD GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Affimed N.V.
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Values in USD · ADR · Reports in EUR
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Did you know?
Price sits at 13% of its 52-week range.
Current Price
$0.18
+0.00%Profile
Valuation (TTM)
Market Cap$2.78M
P/E-0.03
EV—
P/B0.04
Shares Out15.30M
P/Sales2.88
Revenue$965180.77
EV/EBITDA—
Affimed N.V. (AFMD) Quality Analysis
AFMD Profitability
Profitability trend analysis coming soon
AFMD Growth
Growth trend analysis coming soon
AFMD Financial Health
Financial health indicators coming soon
AFMD Quality & Fundamental Analysis
Affimed N.V. (AFMD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Affimed N.V.'s financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Affimed N.V. has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -7949.55% and a return on equity (ROE) of -119.46%. Return on assets (ROA) stands at -71.08%.
The debt-to-equity ratio is 0.33, with a current ratio of 3.25. Operating margin is -1288.95%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Affimed N.V. is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.